Lamivudine Arrow (Lamivudine)

Lamivudine is a nucleoside analogue that is converted inside cells to its active triphosphate form. This active metabolite competes with natural nucleotides for incorporation by HIV reverse transcriptase and hepatitis B virus DNA polymerase, causing premature termination of viral DNA synthesis and thereby inhibiting viral replication.

The appropriate dose of Lamivudine Arrow is determined by the prescribing healthcare professional based on the individual’s clinical condition, weight, renal function and treatment regimen. Patients should follow the exact dosing instructions provided by their prescriber and not adjust the dose on their own.

Safety of Lamivudine Arrow in pregnancy or lactation should be evaluated by a qualified clinician. The potential benefits to the mother must be weighed against any possible risks to the fetus or infant. Use is generally considered only when clearly needed, and breastfeeding decisions should follow local guidelines.

To order Lamivudine Arrow, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class and is often combined with other antiretrovirals for synergistic effect. Compared with some older NRTIs, lamivudine has a favorable safety profile, lower mitochondrial toxicity, and is effective against both HIV and hepatitis B, making it a versatile component of combination regimens.

Lamivudine Arrow should be stored at temperatures below 25 °C in its original packaging. Protect the product from moisture, direct sunlight and excessive heat. Keep the container tightly closed and out of reach of children to maintain potency throughout its shelf life.

Lamivudine Arrow is taken orally, usually with or without food, as directed by the prescribing clinician. The tablets (or other oral dosage form) should be swallowed whole with a glass of water. Patients should not crush, chew, or split the tablets unless specifically instructed.

Serious adverse events, although rare, include lactic acidosis, severe hepatotoxicity and pancreatitis. These conditions can be life‑threatening and require immediate medical attention. Patients should be monitored for signs such as unexplained fatigue, abdominal pain, jaundice or rapid breathing, and report any concerning symptoms promptly.

Lamivudine Arrow should be avoided in individuals with known hypersensitivity to lamivudine or any of its excipients. Caution is also advised for patients with severe renal or hepatic impairment, and those taking contraindicated medications such as didanosine, stavudine or ribavirin without proper medical supervision.